MA30663B1 - Derives d'ester de l'acide aminophosphorique et modulateur du recepteur s1p contenant ledit derive en tant que principe actif - Google Patents

Derives d'ester de l'acide aminophosphorique et modulateur du recepteur s1p contenant ledit derive en tant que principe actif

Info

Publication number
MA30663B1
MA30663B1 MA31663A MA31663A MA30663B1 MA 30663 B1 MA30663 B1 MA 30663B1 MA 31663 A MA31663 A MA 31663A MA 31663 A MA31663 A MA 31663A MA 30663 B1 MA30663 B1 MA 30663B1
Authority
MA
Morocco
Prior art keywords
derivative
active ingredient
acid ester
receptor modulator
ester derivatives
Prior art date
Application number
MA31663A
Other languages
English (en)
Inventor
Yasushi Kohno
Kiyoshi Fujii
Tatsuhiro Saito
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MA30663B1 publication Critical patent/MA30663B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)

Abstract

Fournir un dérivé aminophosphorique ayant une excellente activité modulatoire dU récepteur de sphingosine-1-phosphate (S1P). Suite aux recherches intensives continues pour créer un composé fortement sûr qui a une activité modulatoire sur le récepteur de S1P, il a été découvert que le dérivé aminophosphorique représenté par la formule générale (1) suivante, a une forte action activité modulatoire sur le récepteur de S1P.
MA31663A 2006-08-08 2009-02-26 Derives d'ester de l'acide aminophosphorique et modulateur du recepteur s1p contenant ledit derive en tant que principe actif MA30663B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006215280 2006-08-08

Publications (1)

Publication Number Publication Date
MA30663B1 true MA30663B1 (fr) 2009-08-03

Family

ID=39032957

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31663A MA30663B1 (fr) 2006-08-08 2009-02-26 Derives d'ester de l'acide aminophosphorique et modulateur du recepteur s1p contenant ledit derive en tant que principe actif

Country Status (26)

Country Link
US (1) US8232319B2 (fr)
EP (1) EP2058317B1 (fr)
JP (1) JP5188972B2 (fr)
KR (1) KR101339976B1 (fr)
CN (1) CN101501049B (fr)
CA (1) CA2659598A1 (fr)
CY (1) CY1114681T1 (fr)
DK (1) DK2058317T3 (fr)
ES (1) ES2438265T3 (fr)
HR (1) HRP20131172T1 (fr)
IL (1) IL196275A (fr)
MA (1) MA30663B1 (fr)
ME (1) ME02095B (fr)
MX (1) MX2009001456A (fr)
MY (1) MY152176A (fr)
NO (1) NO20090606L (fr)
NZ (1) NZ574011A (fr)
PL (1) PL2058317T3 (fr)
PT (1) PT2058317E (fr)
RS (1) RS53080B (fr)
RU (1) RU2430925C2 (fr)
SG (1) SG174028A1 (fr)
SI (1) SI2058317T1 (fr)
TN (1) TNSN08545A1 (fr)
WO (1) WO2008018427A1 (fr)
ZA (1) ZA200900206B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009142194A1 (fr) * 2008-05-19 2009-11-26 杏林製薬株式会社 Procédé de production d’un dérivé d’aminoalcool optiquement actif
CA2724592A1 (fr) 2008-05-20 2009-11-26 Kyorin Pharmaceutical Co., Ltd. Agent d~induction/d~entretien de remission
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) * 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
HRP20141065T1 (hr) * 2009-07-09 2015-02-13 Kyorin Pharmaceutical Co., Ltd. Derivati difenil-sulfida i lijekovi koji ih sadrže kao aktivni sastojak
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
JP2014518554A (ja) * 2011-04-18 2014-07-31 アラーガン インコーポレイテッド スフィンゴシン−１リン酸受容体調節剤としての置換二環式メチルアミン誘導体
CN102863345A (zh) * 2011-07-06 2013-01-09 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
JPWO2015194157A1 (ja) * 2014-06-16 2017-04-20 杏林製薬株式会社 ジフェニルスルフィド誘導体の製造方法及び製造中間体
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
PL3465889T3 (pl) 2016-06-07 2021-10-25 Tesla, Inc. Zabezpieczenie przed wyładowaniem rotora silnika elektrycznego
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
US10967702B2 (en) 2017-09-07 2021-04-06 Tesla, Inc. Optimal source electric vehicle heat pump with extreme temperature heating capability and efficient thermal preconditioning
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
PY2011993A (es) 2019-02-26 2021-07-05 Bayer Ag Derivados heterocíclos bicíclicos condensados como plaguicida
CA3201000A1 (fr) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Procedes de traitement d'etats lies au recepteur s1p1
US11932078B2 (en) 2021-03-31 2024-03-19 Tesla, Inc. Electric vehicle heat pump using enhanced valve unit

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050327B1 (fr) * 1980-10-21 1984-06-20 Roche Diagnostics GmbH Phospholipides contenant du soufre, leur procédé de préparation et médicaments contenant ces composés
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
EP1092435B1 (fr) 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Medicaments antidiabetiques
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (fr) 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
EP1315735A4 (fr) 2000-08-31 2005-04-06 Merck & Co Inc Derives de phosphates utilises en tant qu'agents immuno-regulateurs
JP2004529100A (ja) 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト
WO2002062389A1 (fr) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
JP4318921B2 (ja) 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
CA2442178A1 (fr) 2001-03-26 2002-10-03 Novartis Ag Derives de 2-amino-propanol
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ES2316613T3 (es) 2001-05-10 2009-04-16 Ono Pharmaceutical Co., Ltd. Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
US20040138462A1 (en) 2001-05-24 2004-07-15 Minoru Sakurai Aminoalcohol derivatives
EP1424078A4 (fr) 2001-09-04 2009-03-25 Ono Pharmaceutical Co Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
CA2461212C (fr) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005112721A (ja) 2001-11-06 2005-04-28 Maruha Corp 含窒素化合物、製造法、及びその利用方法
WO2003051876A1 (fr) 2001-12-14 2003-06-26 Japan Tobacco Inc. Derives de pyrazolopyridine et son utilisation medicinale
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
JP4771511B2 (ja) 2003-07-08 2011-09-14 第一三共株式会社 アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
WO2003061567A2 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003074008A2 (fr) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
JPWO2004002531A1 (ja) 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
CN100516024C (zh) 2002-09-13 2009-07-22 诺瓦提斯公司 氨基-丙醇衍生物
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
EP1575576A2 (fr) 2002-09-24 2005-09-21 Novartis AG Composes organiques
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
DE60335827D1 (de) 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
PL378134A1 (pl) 2003-02-11 2006-03-06 Irm Llc Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
BRPI0407658A (pt) * 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
CN1777575B (zh) 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
MXPA05011597A (es) 2003-04-30 2005-12-15 Novartis Ag Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012459A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
EP1644367B1 (fr) 2003-05-19 2015-10-14 Novartis AG Compositions et composes immunosuppresseurs
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
WO2005014603A1 (fr) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Composes de phosphinane a effet immunomodulateur
WO2005014525A2 (fr) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Compose bi-aryle presentant une activite immunosuppressive
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005044780A1 (fr) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7718704B2 (en) 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0411929D0 (en) 2004-05-27 2004-06-30 Novartis Ag Organic compounds
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
WO2006041015A1 (fr) 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. Dérivé d’aminoalcool, sel d’addition dudit dérivé, et agent immunosuppresseur
EP1806338B1 (fr) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Procédé de synthèse de l hydrochlorure de 2-amino-2-[2-[4-(3-benzyloxy-phénylthio)-2-chlorophényl[éthyl]-1,3-propanediol et des hydrates de ce composé, et intermédiaires de synthèse de celles-ci
WO2006063033A2 (fr) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Analogues d'aryl amide sphingosine 1-phosphate
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
ES2529724T3 (es) 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes
PL1932522T3 (pl) 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
US8546452B2 (en) 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2007126042A1 (fr) 2006-04-28 2007-11-08 Mitsubishi Tanabe Pharma Corporation Compose 2-aminobutanol et son utilisation a but medical
ZA200900316B (en) 2006-07-25 2010-05-26 Alcon Res Ltd Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders
US7877152B2 (en) 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
AU2007282536A1 (en) 2008-02-14
PT2058317E (pt) 2013-12-11
HK1131154A1 (en) 2010-01-15
JP5188972B2 (ja) 2013-04-24
US8232319B2 (en) 2012-07-31
EP2058317B1 (fr) 2013-10-16
CN101501049A (zh) 2009-08-05
IL196275A0 (en) 2009-09-22
EP2058317A4 (fr) 2011-06-29
ME02095B (fr) 2014-06-30
ZA200900206B (en) 2009-12-30
NO20090606L (no) 2009-03-03
TNSN08545A1 (en) 2010-04-14
NZ574011A (en) 2011-10-28
RU2430925C2 (ru) 2011-10-10
US20090325907A1 (en) 2009-12-31
SG174028A1 (en) 2011-09-29
IL196275A (en) 2013-10-31
KR20090046929A (ko) 2009-05-11
RS53080B (sr) 2014-06-30
RU2009106934A (ru) 2010-09-20
CA2659598A1 (fr) 2008-02-14
DK2058317T3 (da) 2014-01-06
JPWO2008018427A1 (ja) 2009-12-24
PL2058317T3 (pl) 2014-03-31
CY1114681T1 (el) 2016-10-05
MY152176A (en) 2014-08-15
HRP20131172T1 (hr) 2014-01-17
EP2058317A1 (fr) 2009-05-13
SI2058317T1 (sl) 2014-01-31
WO2008018427A1 (fr) 2008-02-14
MX2009001456A (es) 2009-02-19
ES2438265T3 (es) 2014-01-16
KR101339976B1 (ko) 2013-12-10
CN101501049B (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
MA30663B1 (fr) Derives d&#39;ester de l&#39;acide aminophosphorique et modulateur du recepteur s1p contenant ledit derive en tant que principe actif
MA31625B1 (fr) Composition pesticide potentialisee en efficacite et methode pour la potentialisation l&#39;efficacite d&#39;ingredients pesticides actifs
MA29629B1 (fr) Inhibiteurs de l&#39;histone deacetylase
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
MX2010004232A (es) Compuesto de indolina de pirimidilo.
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR112014032873A2 (pt) derivado de éster de ácido 2-aminonicotínico, e, bactericida
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
TN2011000659A1 (fr) Formulation pharmaceutique
MX2009002220A (es) Sistemas y metodos desinfectantes.
AR065093A1 (es) Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112012027385A2 (pt) composição para o controle de doenças de plantas e uso da mesma
EA201391775A1 (ru) Производное азола, способ его получения, промежуточное соединение и химический агент, предназначенный для применения в сельском хозяйстве и садоводстве, и агент для защиты промышленных материалов
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l&#39;acetyl-coa carboxylase
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
MA32929B1 (fr) Lactames en tant qu&#39;inhibiteurs de bêta-sécrétase
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
WO2011109767A3 (fr) Inhibiteurs de la gélatinase et promédicaments
MX2020003993A (es) Derivados de bencimidazol y sus usos.
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية